coagulation factor News
-
Amerigo Scientific Launches New Polyclonal Antibody to Human Blood Coagulation Factor XIII
Amerigo Scientific, a distributor focused on providing critical products and services to the biomedical and life science communities, recently announced the launch of its new polyclonal antibody to human blood coagulation factor XIII to support researchers in life science fields for the detection of blood coagulation factor XIII. This antibody is used for research only, not for human, therapeutic ...
-
ASC Therapeutics Receives Key Regulatory Designations in U.S. and Europe to Advance its Second-Generation Gene Therapy for Hemophilia A
ASC Therapeutics, a privately held biopharmaceutical company pioneering the development of transformative in-vivo gene replacement, gene editing and allogeneic cell therapies for hematologic, metabolic, and other rare diseases has received from the United States (U.S.) Food and Drug Administration (FDA) the Fast Track Designation for ASC618, a second-generation gene therapy of hemophilia A. In ...
-
Bayer receives U.S. FDA Fast Track Designation for asundexian atrial fibrillation program
The OCEANIC-AF (atrial fibrillation) study with asundexian is part of the Phase III OCEANIC clinical trial program enrolling more than 27,000 patients in over 40 countries Asundexian is being evaluated as a potential improved treatment option in stroke prevention and could be part of an entirely new class of treatment options in thrombosis management that aims to uncouple efficacy from ...
By Bayer AG
-
ASC Therapeutics Announces Podium and Poster Presentations of IND-Enabling Studies for ASC618, a Second-Generation Gene Therapy for Hemophilia A, at the 25th ASGCT Meeting, May 16-19, 2022 in Washington, D.C.
Podium presentation highlights significant transduction and transgene expression in pharmacokinetic studies in mice, non-human primates and a humanized liver model Poster presentation focuses on pharmacology, toxicology and safety studies Poster presentation focuses on the development of a novel transduction assay to evaluate in-vitro relative Infectivity ASC Therapeutics, a privately held ...
-
Bayer initiates landmark Phase III study program to investigate oral FXIa inhibitor asundexian
The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke events in patients with atrial fibrillation as well as patients with a non-cardioembolic ischemic stroke or high-risk transient ischemic attack involving up to 30,000 patients Bayer drives the development of its FXIa inhibitor, with the goal of offering a ...
By Bayer AG
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you